Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 28;5(3):578-583.
doi: 10.1002/jha2.909. eCollection 2024 Jun.

Clinical outcomes of patients receiving three versus four doses of methotrexate with concomitant antithymocyte globulin in match unrelated donor allogeneic stem cell transplant: A single-center experience

Kittika Poonsombudlert  1 , Sarah Mott  1 , Benda Miller  1 , Ratdanai Yodsuwan  1 , Hira Shaikh  1 , Christopher Strouse  1 , Jonathan Lochner  1 , Umar Farooq  1 , Margarida Magalhaes-Silverman  1
Affiliations

Clinical outcomes of patients receiving three versus four doses of methotrexate with concomitant antithymocyte globulin in match unrelated donor allogeneic stem cell transplant: A single-center experience

Kittika Poonsombudlert et al. EJHaem. .

Abstract

Methotrexate (MTX) doses on days +1, +3, +6, and +11 after match unrelated donor allogeneic stem cell transplant (MUD HSCT) is a common graft-versus-host disease (GVHD) prophylaxis regimen. However, the overlapping toxicity of MTX with conditioning chemotherapy sometimes warrants the omission of the fourth dose of MTX. Prior single-institution studies showed conflicting results comparing the outcomes of patients who received three versus four doses of MTX, but to our knowledge, the effect of concomitant antithymocyte globulin (ATG) has not been reported. Charts of patients who underwent MUD HSCT between 2009 and 2023 were reviewed. Patients received rabbit ATG (Thymoglobulin), given at 0.5 mg/kg on day -3, 2 mg/kg on day -2, and 2.5 mg/kg on day -1. MTX is given at 15 mg/m2 on day +1 and 10 mg/m2 on days +3, +6, and +11. Severe mucositis was the most common indication for day +11 MTX omission (82%). We identified 292 patients (116 in 3 dose cohort and 176 in 4 dose cohort). Median follow-up was 23 months (range 1-151). Patients in the 4 doses cohort were more frequently male (68% vs. 50%, p < 0.01), received a reduced intensity conditioning regimen (38.0% vs. 22%, p < 0.01), were older (median 58 vs. 54 years, p = 0.02), and received a transplant in the earlier era (median HSCT year 2014 vs. 2018, p < 0.01). A statistically significant difference was not evidenced between the cohorts for the following outcomes: acute GVHD (aGVHD) (HR 1.1, 95% CI 0.9-1.5), chronic GVHD (cGVHD) (HR 1.3, 95% CI 0.8-1.6), relapse-free survival (RFS) (HR 1.0, 95% CI 0.6-1.5), non-relapse mortality (NRM) (HR 1.4, 95% CI 0.9-2.2), and overall survival (OS) (HR 1.2, 95% CI 0.9-1.7). Both cohorts had similar median time to neutrophil engraftment at 14 days. When ATG is incorporated, omission of day +11 MTX does not significantly impact the rate of engraftment or cumulative incidence of aGVHD, cGVHD, RFS, NRM, and OS.

Keywords: GVHD prophylaxis; antithymocyte globulin; match unrelated allogeneic stem cell transplant; methotrexate.

PubMed Disclaimer

Conflict of interest statement

All authors declare no conflict of interest pertinent to this manuscript.

Figures

FIGURE 1
FIGURE 1
Cumulative incidence of acute graft‐versus‐host disease (aGVHD).
FIGURE 2
FIGURE 2
Cumulative incidence of chronic graft‐versus‐host disease (cGVHD).
FIGURE 3
FIGURE 3
Overall survival (OS).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Deeg HJ, Spitzer TR, Cottler‐Fox M, Cahill R, Pickle LW. Conditioning‐related toxicity and acute graft‐versus‐host disease in patients given methotrexate/cyclosporine prophylaxis. Bone Marrow Transplant. 1991;7(3):193–198. - PubMed
    1. Mohty M, Balere M‐L, Socie G, Milpied N‐J, Ifrah N, Kuentz M, et al. Antithymocyte globulins (ATG) as part of the myeloablative conditioning (MAC) regimen can reduce the risk of severe graft‐vs.‐host disease (GVHD) after allogeneic stem cell transplantation (allo‐SCT) from matched‐unrelated donors (MUD). Blood. 2008;112(11):420–421.
    1. Othman J, Greenwood M, Moore J, Larsen S, Watson A‐M, Arthur C, et al. Unrelated donor transplant recipients given thymoglobuline have superior GRFS when compared to matched related donor recipients undergoing transplantation without ATG. Biol Blood Marrow Transplant. 2020;26(10):1868–1875. 10.1016/j.bbmt.2020.06.030 - DOI - PubMed
    1. Kumar S, Wolf RC, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, et al. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft‐versus‐host disease. Bone Marrow Transplant. 2002;30(3):161–165. 10.1038/sj.bmt.1703616 - DOI - PubMed
    1. Nakamura N, Wada F, Kondo T, Aoki K, Arai Y, Mizumoto C, et al. Significance of omitting day 11 mini‐dose methotrexate for GVHD prophylaxis after unrelated bone marrow transplantation. Transplant Cell Ther. 2023;29(2):119 e1–119.e7. 10.1016/j.jtct.2022.11.006 - DOI - PubMed